Effect of Clarithromycin on the Pharmacokinetics of Pranlukast in Healthy Volunteers

Pranlukast is a cysteinyl leukotriene receptor adversary that has been acclimated to amusement bronchial asthma and allergic rhinitis. In vitro abstracts advance that pranlukast is a substrate of CYP3A4. Thus, the aftereffect of clarithromycin, a almighty CYP3A4 inhibitor, on the pharmacokinetics of pranlukast was advised in an open-label, randomized, two-way crossover abstraction in 16 advantageous macho volunteers.
In analysis A, volunteers accustomed a single, 225 mg dosage of pranlukast. In analysis B, 200 mg of clarithromycin was administered alert circadian for 7 canicule and a single, 225 mg dosage of pranlukast was coadministered on day 7. Blood samples were calm up to 24 hours afterwards treatment, and pranlukast concentrations in the claret were measured.
The geometric beggarly ratios [GMR] (90% aplomb intervals [CIs]) for pranlukast AUC0-∞ and Cmax (with/without clarithromycin) were 1.06 (0.91, 1.24) and 1.17 (0.95, 1.45), respectively. In conclusion, clarithromycin and pranlukast could be coadministered after dosage acclimation because clarithromycin minimally afflicted the pharmacokinetics of pranlukast.